Daniel Erskine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3234639/publications.pdf

Version: 2024-02-01

39 papers 1,339 citations

394421 19 h-index 35 g-index

41 all docs

41 docs citations

times ranked

41

2202 citing authors

#	Article	IF	CITATIONS
1	Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 2019, 14, 5.	10.8	203
2	Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathologica, 2017, 134, 459-473.	7.7	180
3	TDPâ€43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. Brain Pathology, 2017, 27, 472-479.	4.1	170
4	Parkinson's disease biomarkers based on αâ€synuclein. Journal of Neurochemistry, 2019, 150, 626-636.	3.9	104
5	$\hat{l}\pm$ -Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2109617119.	7.1	60
6	Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathologica Communications, 2016, 4, 66.	5.2	58
7	Antibodies against alphaâ€synuclein: tools and therapies. Journal of Neurochemistry, 2019, 150, 612-625.	3.9	53
8	Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discovery Today, 2019, 24, 2307-2314.	6.4	33
9	Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies. Movement Disorders, 2017, 32, 414-422.	3.9	32
10	Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathologica, 2021, 141, 511-526.	7.7	31
11	Regional levels of physiological $\hat{l}\pm$ -synuclein are directly associated with Lewy body pathology. Acta Neuropathologica, 2018, 135, 153-154.	7.7	30
12	Neuronal Loss and \hat{f} -Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. American Journal of Geriatric Psychiatry, 2017, 25, 595-604.	1.2	29
13	Heterogeneity in αâ€synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. Neuropathology and Applied Neurobiology, 2019, 45, 597-608.	3.2	27
14	Inflammation in dementia with Lewy bodies. Neurobiology of Disease, 2022, 168, 105698.	4.4	26
15	Forecasting stroke-like episodes and outcomes in mitochondrial disease. Brain, 2022, 145, 542-554.	7.6	25
16	Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. Movement Disorders, 2018, 33, 982-991.	3.9	24
17	Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease. Brain Pathology, 2019, 29, 414-424.	4.1	24
18	Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. Acta Neuropathologica Communications, 2022, 10, .	5.2	24

#	Article	IF	CITATIONS
19	Changes to the lateral geniculate nucleus in A lzheimer's disease but not dementia with L ewy bodies. Neuropathology and Applied Neurobiology, 2016, 42, 366-376.	3.2	22
20	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts. Journal of Neural Transmission, 2017, 124, 671-683.	2.8	21
21	Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. Neuroscience Bulletin, 2019, 35, 295-300.	2.9	15
22	Investigating the presence of doubly phosphorylated î±â€synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. Brain Pathology, 2020, 30, 831-843.	4.1	15
23	RT-QuIC Using C-Terminally Truncated \hat{l}_{\pm} -Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies. Biomolecules, 2021, 11, 820.	4.0	14
24	Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease. Movement Disorders, 2022, 37, 302-314.	3.9	14
25	Generation of monoclonal antibodies against phosphorylated $\hat{l}\pm$ -Synuclein at serine 129: Research tools for synucleinopathies. Neuroscience Letters, 2020, 725, 134899.	2.1	12
26	Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls. Acta Neuropathologica, 2020, 139, 219-221.	7.7	11
27	Concomitant LATEâ€NC in Alzheimer's disease is not associated with increased tau or amyloidâ€Î² pathological burden. Neuropathology and Applied Neurobiology, 2020, 46, 722-734.	3.2	11
28	Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 103.	5.2	10
29	Hippocampal network hyperexcitability in young transgenic mice expressing human mutant alpha-synuclein. Neurobiology of Disease, 2021, 149, 105226.	4.4	10
30	Novel engineered nanobodies specific for Nâ€terminal region of alphaâ€synuclein recognize Lewyâ€body pathology and inhibit <i>inâ€vitro</i> seeded aggregation and toxicity. FEBS Journal, 2022, 289, 4657-4673.	4.7	9
31	Prion-like α-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	7.6	9
32	Blood mRNA Expression in Alzheimer's Disease and Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2022, 30, 964-975.	1.2	9
33	Neurodegenerative Diseases and Ageing. Sub-Cellular Biochemistry, 2019, 91, 75-106.	2.4	8
34	Insights into Lewy body disease from rare neurometabolic disorders. Journal of Neural Transmission, 2021, 128, 1567-1575.	2.8	7
35	Stereological approaches to dementia research using human brain tissue. Journal of Chemical Neuroanatomy, 2016, 76, 73-81.	2.1	5
36	[P3â€"418]: PARIETAL WHITE MATTER LESIONS IN ALZHEIMER's DISEASE ARE ASSOCIATED WITH CORTICAL NEURODEGENERATIVE PATHOLOGY AND NOT WITH SMALLâ€VESSEL DISEASE. Alzheimer's and Dementia, 2017, 13, P1125.	0.8	0

3

#	Article	IF	CITATIONS
37	[P3–426]: TISSUE MICROARRAY AND QUANTITATIVE NEUROPATHOLOGY: A HIGH THROUGHPUT METHODOLOGY FOR NEUROPATHOLOGICAL ASSESSMENT OF LARGE SCALE COHORTS. Alzheimer's and Dementia, 2017, 13, P1131.	0.8	0
38	P1â€101: FEASIBILITY STUDY OF SYNCHROTRONâ€BASED MICROTOMOGRAPHY TO IDENTIFY αâ€SYNUCLEIN OLIGOMERS IN POSTMORTEM TISSUE. Alzheimer's and Dementia, 2018, 14, P310.	0.8	0
39	Cellular vulnerability in Lewy body diseases. Alzheimer's and Dementia, 2020, 16, e041743.	0.8	0